Evidence map›Paper›PMID 36060324›Full record

ArticleCureus2022

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget's Disease.

Gary W Takahashi, John Vetto, Justin J Leitenberger, Arthur Hung

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gary W TakahashiHematology & Medical Oncology, Oregon Health & Science University, Portland, USA.
John VettoSurgical Oncology, Oregon Health & Science University, Portland, USA.
Justin J LeitenbergerDermatologic Surgery, Oregon Health & Science University, Portland, USA.
Arthur HungRadiation Oncology, Oregon Health & Science University, Portland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Published systemic therapy options for metastatic extramammary Paget's disease have largely been anecdotal due to the rarity of this disease, which has precluded the ability to conduct clinical trials. We describe the favorable response of a 72-year-old man with extramammary Paget's disease, whose disease has been controlled with the CDK4/6 inhibitor, abemaciclib. The rationale behind the selection of this therapy is discussed.

Indexed as

abemaciclibcutaneous adenocarcinomacyclin d kinase inhibitorsextramammary paget's diseasetargeted therapy

Identifiers

PMID36060324
PMCPMC9428388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.